Back to top
more

Henry Schein (HSIC)

(Real Time Quote from BATS)

$68.44 USD

68.44
593,312

+1.07 (1.59%)

Updated Sep 18, 2025 02:44 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.64%
2Buy17.83%
3Hold9.69%
4Sell5.29%
5Strong Sell2.54%
S&P50011.29%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 40% (147 out of 245)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Myriad Genetics (MYGN) to Offer Companion Diagnostic for Lynparza

by Zacks Equity Research

Myriad Genetics' (MYGN) BRACAnalysis CDx gained FDA nod for identifying breast cancer patients eligible for treatment with Lynparza.

Zacks Equity Research

Here's Why You Should Retain Illumina (ILMN) Stock For Now

by Zacks Equity Research

Investors are optimistic about Illumina's (ILMN) better-than-expected results and strategic collaborations.

Zacks Equity Research

Has Henry Schein (HSIC) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Henry Schein (HSIC) and Innoviva (INVA) have performed compared to their sector so far this year.

Zacks Equity Research

Here's Why You Should Retain Masimo (MASI) Stock For Now

by Zacks Equity Research

Investors continue to be optimistic about Masimo (MASI) owing to its focus on patient monitoring.

Zacks Equity Research

Here's Why You Should Hold on to LabCorp (LH) Stock For Now

by Zacks Equity Research

Investors are optimistic about LabCorp's (LH) better-than-expected results and robust base business performance.

Zacks Equity Research

Here's Why You Should Hold on to CONMED (CNMD) Stock Now

by Zacks Equity Research

CONMED (CNMD) continues to gain momentum from a solid product portfolio and strong General Surgery business. However, data security threats linger.

Zacks Equity Research

Reasons to Add Quidel (QDEL) Stock To Your Portfolio Now

by Zacks Equity Research

Investors continue to be optimistic about Quidel (QDEL) owing to its strong diagnostics portfolio.

Zacks Equity Research

Here's Why You Should Hold on to PerkinElmer (PKI) Stock Now

by Zacks Equity Research

PerkinElmer (PKI) continues to gain momentum from a solid product portfolio and healthy margins. However, forex woes linger.

Zacks Equity Research

Allscripts (MDRX) Unveils Newly Rebranded App Expo Site

by Zacks Equity Research

Allscripts' (MDRX) rebranded App Expo site to offer developers an opportunity to present their certified solutions online.

Zacks Equity Research

Here's Why You Should Retain Syneos Health (SYNH) For Now

by Zacks Equity Research

Investors are optimistic about Syneos Health's (SYNH) better-than-expected earnings and robust segmental performance.

Zacks Equity Research

Reasons to Retain Catalent (CTLT) Stock in Your Portfolio

by Zacks Equity Research

Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.

Zacks Equity Research

Nevro's (NVRO) PDN Therapy Gets Noridian's Medicare Coverage

by Zacks Equity Research

Latest favorable coverage decision for Nevro's (NVRO) PDN Therapy by Noridian is expected to allow the former to serve a wider patient pool.

Zacks Equity Research

Here's Why You Should Retain DENTSPLY SIRONA (XRAY) Now

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) continues to gain traction from a robust product portfolio. However, forex woes persist.

Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 System Gets Chosen by CARTI

by Zacks Equity Research

Accuray's (ARAY) CyberKnife S7 System gets selected by the CARTI medical care team, thereby offering better cancer care in Arkansas via expanded access to advanced technology.

Zacks Equity Research

Quest Diagnostics (DGX) Base Sales Recover Amid Price Woe

by Zacks Equity Research

Quest Diagnostics (DGX) raises 2022 guidance based on the continued rebound in base business and recent investments expected to accelerate growth.

Zacks Equity Research

Allscripts (MDRX) Inks Divestment Deal to Focus on Core Wing

by Zacks Equity Research

Constellation Software will purchase the net assets of Allscripts' (MDRX) Hospitals and Large Physician Practices business segment via its wholly-owned subsidiary.

Zacks Equity Research

Here's Why You Should Retain West Pharmaceutical (WST) Now

by Zacks Equity Research

West Pharmaceutical (WST) continues to gain momentum due to its strength in the Proprietary Products business. However, forex woes persist.

Zacks Equity Research

Bio-Rad's (BIO) Product Launches Aid Growth, Global Arm Strong

by Zacks Equity Research

Bio-Rad's (BIO) Diagnostics business registers growth across all its product lines, driven by the recovery of routine testing.

Zacks Equity Research

Alcon (ALC) Expands in the U.S. With New Clareon IOLs Launch

by Zacks Equity Research

With the latest launch, Alcon's (ALC) Clarion Monofocal, Clareon PanOptix, Clareon PanOptix Toric, Clareon Vivity and Clareon Vivity Toric IOLs are now available in the United States.

Zacks Equity Research

Merit Medical's (MMSI) Product Included in FDA's Program

by Zacks Equity Research

Receipt of the Breakthrough Device Designation for Merit Medical's (MMSI) Embosphere Microspheres is expected to improve patient outcome.

Zacks Equity Research

Henry Schein (HSIC) Hits 52-Week High, Can the Run Continue?

by Zacks Equity Research

Henry Schein (HSIC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks Equity Research

Here's Why You Should Retain Chemed (CHE) Stock For Now

by Zacks Equity Research

Investors are optimistic about Chemed's (CHE) better-than-expected earnings and robust performance by the Roto-Rooter arm.

Zacks Equity Research

Here's Why You Should Retain SmileDirectClub (SDC) For Now

by Zacks Equity Research

Investors are optimistic about SmileDirectClub's (SDC) strategic collaborations and product launches.

Zacks Equity Research

Here's Why You Should Hold on to Stryker (SYK) Stock for Now

by Zacks Equity Research

Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.

Zacks Equity Research

PacBio (PACB) Supports SickKids With Sequencing Technology

by Zacks Equity Research

PacBio (PACB) to help SickKids in detecting potential genetic causes of a range of medical and developmental conditions.